Taysha Gene Therapies, Inc.
TSHA
$6.86
$0.010.07%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -96.99% | -48.26% | -28.24% | -28.45% | 10.52% |
| Total Depreciation and Amortization | 4.24% | -1.64% | -2.72% | -13.98% | -12.92% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 55.76% | 184.86% | -56.80% | 24.02% | 3.90% |
| Change in Net Operating Assets | -2.15% | -171.90% | 168.53% | 151.99% | -1,628.86% |
| Cash from Operations | -85.64% | -45.96% | -11.80% | 6.15% | -11.22% |
| Capital Expenditure | 93.65% | -12,600.00% | -208.57% | 99.00% | -170.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -42,957.14% | -72.73% | -- | -- | -- |
| Cash from Investing | -715.09% | -2,000.00% | -37.14% | 130.85% | -165.00% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 822.67% | -- | -- | 206.71% | 188.46% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 114.96% | -232.56% | -62.28% | 1,007.69% | -164.58% |
| Cash from Financing | 1,467.31% | 13,981.23% | 33.39% | 206.93% | -136.36% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -92.45% | 221.10% | -2.40% | 302.29% | -12.44% |